How does inotuzumab ozogamicin actually kill leukemia cells?
Inotuzumab ozogamicin is a targeted missile: it binds to CD22 protein on the surface of B-cell leukemia cells, then releases a toxin (calicheamicin) inside the cell that breaks DNA and triggers cell death. This precision targeting spares healthy cells, making it far more selective than old-fashioned chemotherapy [2][5].
In the landmark INO-VATE trial (2016), 61% of patients with relapsed or refractory ALL achieved complete remission with inotuzumab ozogamicin, compared to just 34% on standard salvage chemotherapy—a 27-percentage-point absolute benefit [2]. Median overall survival was 7.7 months versus 6.7 months, and 50% of responders maintained remission for 12 months or longer [5]. These numbers come straight from the FDA label and peer-reviewed oncology journals.
Your leukemia cells have CD22 protein stuck all over them like tiny handles. Inotuzumab ozogamicin grabs those handles, sneaks inside, and releases calicheamicin—a DNA-breaking toxin that forces the cancer cell to self-destruct [2]. Healthy blood cells have far fewer CD22 handles, so they survive the attack. It's like a smart bomb versus a carpet bomb.
The trade-off is real: because inotuzumab ozogamicin is so potent, it can damage your liver (hepatotoxicity) and drop your platelet count dangerously low (thrombocytopenia). Grade 3–4 liver injury occurs in 8–12% of patients, and low platelets in 45–52% [1][5]. Your oncologist will check your blood counts and liver enzymes before every dose and hold treatment if numbers dip too far.
Ask your oncologist: 'Will you check my liver enzymes and platelet count before each infusion, and what numbers would make you pause treatment?' This question ensures you're not blindsided by a delayed cycle.